|[November 04, 2013]
AIMM Therapeutics' Pre-fusion RSV Antibodies Facilitate Improved Approach to Vaccine Development
AMSTERDAM --(Business Wire)--
AIMM Therapeutics B.V., a leading developer of a new generation of
therapeutic antibodies, announced today that researchers have used the
Company's unique family of antibodies that neutralize respiratory
syncytial virus (RSV) to engineer an improved vaccine against RSV. In a
paper published in Science titled 'Structure-Based Design of a
Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus'1,
a team of scientists from the Vaccine Research Center (VRC) at the U.S.
National Institute of Allergy and Infectious Diseases describe how
structural biology insight into how AIMM's highly potent RSV antibodies
work enabled them to engineer a vaccine immunogen able to trigger a
response 40 times higher than needed to neutralize RSV infection.
"Respiratory syncytial virus remains a large unmet medical need. Over
160,000 children per year die worldwide from RSV infections and the
subsequent clinical complications. Although most adults have acquired
immunity, very young children, immune compromised adults, and the
elderly all have a significant risk of complications arising from RSV
infections," noted Hergen Spits, AIMM's Chief Scientific Officer.
"AIMM's technology platforms allow rapid identification of unique and
strongly neutralizing antibodies in blood samples donated by healthy
adults as was the cae here. These antibodies are not only useful in
vaccine development, as this current paper shows, but are being
developed as therapeutics, which will have utility in cases where
vaccines are not effective.
On the surface of RSV, there is a protein simply known as F that
facilitates fusion with human cells during the infection process.
Earlier this year Science published an article titled 'Structure
of RSV fusion glycoprotein trimer bound to a prefusion-specific
neutralizing antibody' describing the unique ability of AIMM's highly
neutralizing antibodies to recognize a prefusion complex of the RSV-F
protein. The research showed that by targeting the RSV-F protein while
it was in the compact prefusion conformation, AIMM's antibodies could
halt the critical unfolding of this protein into the conformation
required for viral entry into cells. Working with this insight,
researchers were able to identify the critical structure that the RSV-F
protein presents to the antibody. Immunizing mice with a stabilized form
of this structure produced an extremely efficient immune response to the
protein that resulted in protection against subsequent challenge with
"This has been an excellent collaboration with Dr. Kwong and his
colleagues at the NIH," said Jan de Vries, Chief Executive Officer at
AIMM. "I think that this research clearly demonstrates how the novel
antibody technology platforms developed by AIMM can be used to inform
future vaccine development, not only in RSV but in several other serious
About AIMM Therapeutics
AIMM Therapeutics (AIMM) is a leading antibody company that based on its
synergistic, state-of-the-art antibody technology platform develops high
affinity human monoclonal antibodies from immortalized and selected B
cells of individuals who produce antibodies with high therapeutic value.
AIMM antibodies can be further affinity matured in a proprietary process
that does not require molecular engineering. AIMM has a broad product
pipeline targeted at pathogenic viruses and bacteria, and is expanding
its pipeline with drug candidates for cancer and inflammatory diseases.
For more information: www.aimmtherapeutics.com.
1 Jason S. McLellan et al, Science 342, 592
[ Back To Technology News's Homepage ]